Work

A Phase II Study (PERSEUS) of Two Doses of EMD 525797 (DI17E6) in Patients (PTS) with Asymptomatic or Mildly Symptomatic Metastatic Castrate-Resistant Prostate Cancer (MCRPC)

Year: 2012

Type: article

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33528-6

Authors: K. Miller, M. Hussain, G. Mordenti, H. Lannert

Institutions: Stiftung Charité, Charité - Universitätsmedizin Berlin, University of Michigan, U-M Rogel Cancer Center, Merck Serono S.A. (Switzerland), Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3003533755

FWCI:

Cites:

Cited by:

Related to: 10